IRCT20180426039421N3已完成2 期
Two-year follow up of a Randomized, Controlled Trial: the Effects of Melatonin on Fatigue Associated with Breast Cancer and Its Adjuvant Treatments
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- Female
入选标准
- •Breast Cancer Stages I, II, III According to Pathological Reports
- •Patients at least 18 Years Old
- •Have Signed a Written Consent
- •Recevieng Adjuvant Chemotherapy and Radiotherapy
- •No Untreated Hypercalcemia
- •No Systolic Blood Pressure Less Than 100 mm Hg
- •No Warfarin Consumption
- •No Methylphenidate Consumption
- •No Sleep Pills During Melatonin Use
- •No TSH>5/5 or <0/5
- •No Pregnancy or Breastfeeding
排除标准
- •Not signing a written consent
研究者
相似试验
已完成
不适用
Four year follow-up of a randomised controlled trial of joint protection for people with rheumatoid arthritis (RA)Musculoskeletal DiseasesRheumatoid arthritisISRCTN12245727Arthritis Research Campaign (ARC) (UK)
尚未招募
不适用
Mid-term follow-up of a randomized controlled trial comparing ultrasound-guided double percutaneous needling versus high-energy extracorporeal shockwave therapy in the treatment of calcific tendinitis of the rotator cuff.NL-OMON51922Spaarne Gasthuis81
已完成
4 期
Six year follow up of children at high hereditary risk of allergy born to mothers participating in the DOMInO Trial.Atopy & Allergic DiseaseInflammatory and Immune System - AllergiesAlternative and Complementary Medicine - Other alternative and complementary medicineInflammatory and Immune System - Normal development and function of the immune systemACTRN12615000498594Women's & Children's Health Research Institute668
招募中
4 期
To compare the safety and efficacy of amniotic membrane transplantation and cord blood serum in cases of acute chemical injury of the eyeCTRI/2014/09/005067Dr Rajendra Prasad Centre for Ophthalmic Sciences45
已完成
不适用
Retrospective analysis of randomized phase II trial (WJOG6210G) of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with KRAS wild metastatic colorectal cancer refractory to oxaliplatin and bevacizumab to evaluate the association of survival time and treatment efficacy (early tumor shrinkage, depth of response and best overall response) at each armColorectal cancerJPRN-UMIN000031621West Japan Oncology Group117